Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All famotidine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFamotidineFamotidine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study

Dec 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Severe case -81% Improvement Relative Risk Famotidine for COVID-19  Zhou et al.  LATE TREATMENT Is late treatment with famotidine beneficial for COVID-19? PSM retrospective 3,114 patients in China (January - August 2020) Higher severe cases with famotidine (p=0.0001) c19early.org Zhou et al., Gut, December 2020 Favorsfamotidine Favorscontrol 0 0.5 1 1.5 2+
Famotidine for COVID-19
25th treatment shown to reduce risk in October 2021
 
*, now with p = 0.00026 from 30 studies, recognized in 2 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19early.org
Retrospective 4,445 COVID+ patients in China, showing higher risk of combined death/intubation/ICU with famotidine treatment.
risk of severe case, 81.0% higher, HR 1.81, p < 0.001, treatment 72 of 519 (13.9%), control 198 of 2,595 (7.6%), death/intubation/ICU, propensity score matching, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zhou et al., 4 Dec 2020, retrospective, propensity score matching, China, peer-reviewed, 7 authors, study period 1 January, 2020 - 22 August, 2020.
This PaperFamotidineAll
Upregulation of enteric alpha-synuclein as a possible link between inflammatory bowel disease and Parkinson’s disease
Pascal Derkinderen, Wendy Noble, Michel Neunlist, Malvyne Rolli-Derkinderen
Gut, doi:10.1136/gutjnl-2020-323482
PostScript Figure 1 Kaplan-Meier curve stratified by proton pump inhibitor (PPI) use before and after propensity score matching. Figure 2 Kaplan-Meier curve stratified by famotidine use before and after propensity score matching. Provenance and peer review Not commissioned; externally peer reviewed.
Competing interests None declared. Patient consent for publication Not required. ethics approval This study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster. Provenance and peer review Not commissioned; internally peer reviewed. Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise. This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort We..
{ 'indexed': {'date-parts': [[2022, 1, 7]], 'date-time': '2022-01-07T20:09:25Z', 'timestamp': 1641586165944}, 'reference-count': 6, 'publisher': 'BMJ', 'issue': '10', 'license': [ { 'start': { 'date-parts': [[2020, 12, 4]], 'date-time': '2020-12-04T00:00:00Z', 'timestamp': 1607040000000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://bmj.com/coronavirus/usage'}], 'funder': [ { 'DOI': '10.13039/501100001809', 'name': 'National Natural Science Foundation of China', 'doi-asserted-by': 'crossref', 'award': ['72042018, 71972164 and 71672163']}, { 'DOI': '10.13039/501100005847', 'name': 'Health and Medical Research Fund', 'doi-asserted-by': 'crossref', 'award': ['16171991']}, {'name': 'Research Grants Council', 'award': ['Theme‐Based Research Scheme (T32‐102/14N)']}], 'content-domain': {'domain': ['bmj.com'], 'crossmark-restriction': True}, 'short-container-title': ['Gut'], 'published-print': {'date-parts': [[2021, 10]]}, 'DOI': '10.1136/gutjnl-2020-323668', 'type': 'journal-article', 'created': {'date-parts': [[2020, 12, 5]], 'date-time': '2020-12-05T01:16:51Z', 'timestamp': 1607131011000}, 'page': '2012-2013', 'update-policy': 'http://dx.doi.org/10.1136/crossmarkpolicy', 'source': 'Crossref', 'is-referenced-by-count': 21, 'title': [ 'Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity ' 'score-matched territory-wide study'], 'prefix': '10.1136', 'volume': '70', 'author': [ {'given': 'Jiandong', 'family': 'Zhou', 'sequence': 'first', 'affiliation': []}, {'given': 'Xiansong', 'family': 'Wang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sharen', 'family': 'Lee', 'sequence': 'additional', 'affiliation': []}, {'given': 'William Ka Kei', 'family': 'Wu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bernard Man Yung', 'family': 'Cheung', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-6819-0686', 'authenticated-orcid': False, 'given': 'Qingpeng', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-5510-1253', 'authenticated-orcid': False, 'given': 'Gary', 'family': 'Tse', 'sequence': 'additional', 'affiliation': []}], 'member': '239', 'published-online': {'date-parts': [[2020, 12, 4]]}, 'reference': [ { 'key': '2021102004101007000_70.10.2012.1', 'article-title': 'Severe clinical outcomes of COVID-19 associated with proton pump ' 'inhibitors: a nationwide cohort study with propensity score matching', 'author': 'Lee', 'year': '2020', 'journal-title': 'Gut'}, { 'key': '2021102004101007000_70.10.2012.2', 'article-title': 'Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A ' 'meta-analysis', 'author': 'Li', 'year': '2020', 'journal-title': 'Gut'}, { 'key': '2021102004101007000_70.10.2012.3', 'doi-asserted-by': 'publisher', 'DOI': '10.1053/j.gastro.2020.05.053'}, { 'key': '2021102004101007000_70.10.2012.4', 'doi-asserted-by': 'publisher', 'DOI': '10.14309/ajg.0000000000000832'}, { 'key': '2021102004101007000_70.10.2012.5', 'article-title': 'Famotidine use is not associated with 30-day mortality: a Coarsened ' 'exact match study in 7158 hospitalized COVID-19 patients from a large ' 'healthcare system', 'author': 'Yeramaneni', 'year': '2020', 'journal-title': 'Gastroenterology'}, { 'key': '2021102004101007000_70.10.2012.6', 'doi-asserted-by': 'crossref', 'unstructured': 'Cheung KS , Hung IFN , Leung WK . Association between famotidine use and ' 'COVID-19 severity in Hong Kong: a territory-wide study. Gastroenterology ' '2020.doi:10.1053/j.gastro.2020.05.098', 'DOI': '10.1053/j.gastro.2020.05.098'}], 'container-title': ['Gut'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1136/gutjnl-2020-323668', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 10, 20]], 'date-time': '2021-10-20T15:28:20Z', 'timestamp': 1634743700000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 12, 4]]}, 'references-count': 6, 'journal-issue': { 'issue': '10', 'published-online': {'date-parts': [[2021, 9, 8]]}, 'published-print': {'date-parts': [[2021, 10]]}}, 'alternative-id': ['10.1136/gutjnl-2020-323668'], 'URL': 'http://dx.doi.org/10.1136/gutjnl-2020-323668', 'relation': {}, 'ISSN': ['0017-5749', '1468-3288'], 'issn-type': [{'value': '0017-5749', 'type': 'print'}, {'value': '1468-3288', 'type': 'electronic'}], 'subject': ['Gastroenterology'], 'published': {'date-parts': [[2020, 12, 4]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit